| Central venous access devices for paediatric patients with haemophilia: a single-institution experience. | |
| | |
MedLine Citation:
|
PMID: 19149849 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Use of a central venous access device (CVAD) can facilitate early introduction of home-based infusion of factor concentrate for long-term prophylaxis or immune tolerance therapy in children with bleeding disorders. The aim was to review outcomes associated with use of CVAD. Retrospective review of paediatric patients with bleeding disorders was observed at the Mayo Clinic Comprehensive Hemophilia Center. Thirty-seven CVAD were placed in 18 patients (haemophilia A [n = 15], type 3 von Willebrand disease [n = 2] and haemophilia B [n = 1]). Follow-up was for 45 952 CVAD days, and median time that CVAD remained in place was 1361 days per device. Factor VIII (FVIII) inhibitors were present in 4 of the 15 patients. Ten CVAD-related infections occurred (median, 672 days; range, 72-1941 days), of which six were in one patient with FVIII inhibitors. Overall infection rate was 0.22 (95% confidence interval [CI], 0.10-0.40) per 1000 CVAD days, with 0.11 infections in patients without FVIII inhibitors compared with a pooled incidence of 0.66 (95% CI, 0.44-0.97) reported in the literature. Indications for removal of 27 CVAD were blockage, change to peripheral venous access, catheter displacement, infection, leak in the port septum, short catheter and skin erosion. No clinically apparent thrombosis or sequelae of thrombosis were observed. Infection is the most common complication associated with CVAD use and is increased in patients who have inhibitors. The low rate of clinically apparent thrombosis reflects our practice of not screening for thrombosis. The low infection rate reflects our practice of using and reinforcing the aseptic technique. |
| | |
Authors:
|
R Titapiwatanakun; C Moir; R K Pruthi; P L Stavlo; K A Schmidt; V Rodriguez |
Related Documents
:
|
20301819 - Ultrasound-guided continuous femoral nerve block for analgesia after total knee arthrop... 19637959 - Routine replacement versus clinical monitoring of peripheral intravenous catheters in a... 15085039 - Evidence for the use of the antibiotic lock technique. 19285359 - Evaluation of colonisation of peripheral venous catheters inserted by prehospital emerg... 12965069 - Pain after percutaneous nephrolithotomy: impact of nephrostomy tube size. 19854959 - Ultrasound guidance versus electrical stimulation for femoral perineural catheter inser... 1714709 - Low-molecular-weight heparin (enoxaparin) vs dextran 70. the prevention of postoperativ... 21111399 - Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timo... 14974019 - Pre-operative education for hip or knee replacement. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Haemophilia : the official journal of the World Federation of Hemophilia Volume: 15 ISSN: 1365-2516 ISO Abbreviation: Haemophilia Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2009-01-19 Completed Date: 2009-08-04 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 9442916 Medline TA: Haemophilia Country: England |
Other Details:
|
Languages: eng Pagination: 168-74 Citation Subset: IM |
Affiliation:
|
Division of Pediatric Hematology and Oncology, Mayo Clinic, Rochester, Minnesota, USA. rodriguez.vilmarie@mayo.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bacterial Infections
/
etiology Catheterization, Central Venous / adverse effects, instrumentation* Catheters, Indwelling / microbiology Child Child, Preschool Equipment Contamination Factor IX / administration & dosage Factor VIII / administration & dosage*, therapeutic use Hemophilia A / drug therapy* Hemophilia B / drug therapy Home Infusion Therapy / adverse effects, instrumentation* Humans Infant Infusion Pumps, Implantable / microbiology Infusions, Intravenous Male Retrospective Studies von Willebrand Diseases / drug therapy |
| Chemical | |
Reg. No./Substance:
|
9001-27-8/Factor VIII; 9001-28-9/Factor IX |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate...
Next Document: Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for differe...